Role of BRAF mutation in the treatment for melanoma

At the European Cancer Congress (ECC) 2015, Dirk Schadendorf, MD, PhD, from Universitätsklinikum Essen, Essen, Germany, discusses advances in the biological understanding of BRAF-mutant melanoma, which involves the constitutive activation of the MAPK pathway and have led to the development of new targeted therapies for patients with metastatic disease.

Share this video  
Similar topics